title: Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention.
abstract: Pancreatic cancer has a poor prognosis and is associated with high levels of psychological stress that may adversely affect clinical outcomes. However, the potential influence of neuropsychological factors on pancreatic cancer has not been investigated to date. Using a mouse model of social stress, we have tested the hypothesis that psychological stress promotes the progression of pancreatic cancer xenografts via neurotransmitter-induced activation of multiple pathways and that the inhibitory neurotransmitter γ-aminobutiric acid (GABA) inhibits these responses. Sytemic and xenograft levels of noradrenalin, adrenalin, GABA, cortisol, vascular endothelial growth factor (VEGF) and cyclic adenosine 3', 5'-monophosphate (cAMP) were measured by immunoassays. Xenograft expression of nicotinic acetylcholine receptors (nAChRs) α3, α4, α5, α6 and α7 and β-adrenergic receptors 1 and 2 were assessed by real-time PCR and western blots. Expression of glutamate decarboxylases GAD65 and GAD67 and phosphorylated and unphosphorylated signaling proteins of relevance to pancreatic cancer were determined in tumor tissue by western blots. Psychological stress significantly promoted xenograft growth and increased systemic and tumor levels of noradrenalin, adrenalin, cortisol, VEGF and cAMP while GABA and GAD were suppressed. Stress upregulated nAChR proteins but not RNAs and induced phosphorylated ERK, CREB, Src and AKT in xenografts. Reduction of cAMP by treatment with GABA prevented tumor progression and activation of signaling proteins. Our findings suggest that neurotransmitter responses to psychological stress negatively impact clinical outcomes of pancreatic cancer via the activation of multiple pathways and that replacement of the suppressed inhibitory neurotransmitter GABA prevents these effects.
authors.affiliation: Experimental Oncology Laboratory, Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996, USA. hmsch@utk.edu
authors.forename: Hildegard M
authors.initials: HM
authors.lastname: Schuller
authors.forename: Hussein A N
authors.initials: HA
authors.lastname: Al-Wadei
authors.forename: Mohammad F
authors.initials: MF
authors.lastname: Ullah
authors.forename: Howard K
authors.initials: HK
authors.lastname: Plummer
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D000242:Cyclic AMP / Q000502:physiology; D018450:Disease Progression; D004837:Epinephrine / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D009638:Norepinephrine / Q000097:blood; D010190:Pancreatic Neoplasms / Q000209:etiology* / Q000473:pathology; D011978:Receptors, Nicotinic / Q000235:genetics; D015398:Signal Transduction; D013315:Stress, Psychological / Q000150:complications* / Q000378:metabolism; D014183:Transplantation, Heterologous; D005680:gamma-Aminobutyric Acid / Q000096:biosynthesis / Q000494:pharmacology
chemical_list: D011978:Receptors, Nicotinic; D005680:gamma-Aminobutyric Acid; D000242:Cyclic AMP; D006854:Hydrocortisone; D009638:Norepinephrine; D004837:Epinephrine
references.citation: J Cancer Res Clin Oncol. 2005 Oct;131(10):639-48
references.pmid: 16091975
references.citation: Brain Res. 2000 Dec 15;886(1-2):172-189
references.pmid: 11119695
references.citation: Nat Rev Cancer. 2009 Mar;9(3):195-205
references.pmid: 19194381
references.citation: Toxicol Sci. 2007 Mar;96(1):21-9
references.pmid: 17003101
references.citation: Horm Behav. 2008 Feb;53(2):386-94
references.pmid: 18096163
references.citation: J Gastrointest Surg. 2010 Oct;14(10):1566-77
references.pmid: 20824368
references.citation: Methods Enzymol. 2010;485:37-60
references.pmid: 21050910
references.citation: J Psychosom Res. 2009 Mar;66(3):255-8
references.pmid: 19232239
references.citation: Cancer. 2008 Feb 15;112(4):767-78
references.pmid: 18098271
references.citation: Neuro Endocrinol Lett. 2009;30(4):506-10
references.pmid: 20010500
references.citation: Nat Cell Biol. 2000 Jul;2(7):E133-6
references.pmid: 10878827
references.citation: J Pathol. 2009 Aug;218(4):437-45
references.pmid: 19274673
references.citation: Clin Cancer Res. 2006 Jan 15;12(2):369-75
references.pmid: 16428474
references.citation: Cancer Res. 2007 Jul 15;67(14):6863-71
references.pmid: 17638897
references.citation: Toxicol Appl Pharmacol. 2007 Jun 15;221(3):261-7
references.pmid: 17498763
references.citation: Cancer Res. 2007 Oct 15;67(20):9704-12
references.pmid: 17942900
references.citation: Lung Cancer. 2010 Jul;69(1):33-9
references.pmid: 19896235
references.citation: Psychooncology. 2001 Jan-Feb;10(1):19-28
references.pmid: 11180574
references.citation: Clin Cancer Res. 2004 Apr 15;10(8):2846-50
references.pmid: 15102693
references.citation: Curr Treat Options Oncol. 2011 Jun;12(2):111-25
references.pmid: 21461670
references.citation: Carcinogenesis. 1989 Sep;10(9):1753-5
references.pmid: 2569945
references.citation: Cancer Res. 1999 Sep 15;59(18):4510-5
references.pmid: 10493497
references.citation: J Med Chem. 1995 Sep 1;38(18):3415-44
references.pmid: 7658428
references.citation: Transl Oncol. 2011 Apr 01;4(2):83-91
references.pmid: 21461171
references.citation: Oncologist. 2008 May;13(5):562-76
references.pmid: 18515741
references.citation: Crit Rev Oncol Hematol. 2008 Dec;68(3):197-211
references.pmid: 18436450
references.citation: Eur J Neurosci. 2003 Jun;17(11):2313-22
references.pmid: 12814364
references.citation: Cancer Res. 2001 Apr 1;61(7):2866-9
references.pmid: 11306460
references.citation: Pancreas. 2009 May;38(4):416-21
references.pmid: 19169171
references.citation: Life Sci. 2007 Jul 12;81(5):399-404
references.pmid: 17628611
references.citation: Eur J Pharmacol. 2002 Jun 20;446(1-3):83-7
references.pmid: 12098588
references.citation: Carcinogenesis. 2001 Mar;22(3):473-9
references.pmid: 11238189
references.citation: Int Rev Cytol. 2002;213:1-47
references.pmid: 11837891
references.citation: Neuropsychopharmacology. 2010 Jul;35(8):1693-707
references.pmid: 20357756
references.citation: Oncotarget. 2010 Nov;1(7):628-38
references.pmid: 21317458
references.citation: Oncogene. 2011 May 5;30(18):2123-34
references.pmid: 21242978
references.citation: Int J Cancer. 2006 Jun 1;118(11):2744-9
references.pmid: 16381019
references.citation: Int J Oncol. 2002 Jul;21(1):153-7
references.pmid: 12063562
references.citation: Biochem Pharmacol. 2009 Oct 1;78(7):756-65
references.pmid: 19540212
references.citation: Anticancer Res. 2010 Sep;30(9):3279-89
references.pmid: 20944098
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: Carcinogenesis. 2009 Mar;30(3):506-11
references.pmid: 19131543
references.citation: BMC Cancer. 2005 Aug 18;5:104
references.pmid: 16109170
references.citation: Carcinogenesis. 2008 Oct;29(10):1979-85
references.pmid: 18310090
references.citation: Br J Clin Pharmacol. 2011 Jul;72(1):157-61
references.pmid: 21453301
references.citation: Am J Pathol. 2006 Jan;168(1):55-68
references.pmid: 16400009
references.citation: Int J Cancer. 2009 Jul 15;125(2):276-85
references.pmid: 19358273
references.citation: Breast Cancer Res Treat. 2003 Jul;80(1):63-70
references.pmid: 12889599
references.citation: Biochem Pharmacol. 1998 May 1;55(9):1377-84
references.pmid: 10076528
references.citation: Cancer Causes Control. 2004 Aug;15(6):535-41
references.pmid: 15280632
references.citation: Cancer Res. 1995 Aug 15;55(16):3504-8
references.pmid: 7627955